Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes

[1] Fagin JA(2016)Biologic and clinical perspectives on thyroid cancer N. Engl. J. Med. 375 1054-1067

[2] Wells SA(2016)2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid 26 1-133

[3] Haugen BR(2006)Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J. Clin. Endocrinol. Metab. 91 2892-2899

[4] Alexander EK(2019)Controversies, Consensus, and Collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European Thyroid Association Thyroid 29 461-470

[5] Bible KC(2014)Integrated genomic characterization of papillary thyroid carcinoma Cell 159 676-690

[6] Doherty GM(2018)Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers Clin. Cancer Res. 24 3059-3068

[7] Mandel SJ(2017)Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence Clin. Cancer Res. 23 5970-5980

[8] Nikiforov YE(2016)Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers J. Clin. Invest. 126 1052-1066

[9] Pacini F(2015)Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing Hum. Mol. Genet. 24 2318-2329

[10] Randolph GW(2013)Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases J. Clin. Endocrinol. Metab 98 E829-E836

[1] Fagin JA(2016)Biologic and clinical perspectives on thyroid cancer N. Engl. J. Med. 375 1054-1067

[2] Wells SA(2016)2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid 26 1-133

[3] Haugen BR(2006)Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J. Clin. Endocrinol. Metab. 91 2892-2899

[4] Alexander EK(2019)Controversies, Consensus, and Collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European Thyroid Association Thyroid 29 461-470

[5] Bible KC(2014)Integrated genomic characterization of papillary thyroid carcinoma Cell 159 676-690

[6] Doherty GM(2018)Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers Clin. Cancer Res. 24 3059-3068

[7] Mandel SJ(2017)Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence Clin. Cancer Res. 23 5970-5980

[8] Nikiforov YE(2016)Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers J. Clin. Invest. 126 1052-1066

[9] Pacini F(2015)Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing Hum. Mol. Genet. 24 2318-2329

[10] Randolph GW(2013)Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases J. Clin. Endocrinol. Metab 98 E829-E836